Applied DNA Sciences Reports Fiscal First Quarter 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Applied DNA Sciences Reports Fiscal First Quarter 2016 Financial Results

STONY BROOK, NY--(Marketwired - February 10, 2016) -  Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA") (Twitter: @APDN), a provider of DNA-based supply chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, announced financial results for the fiscal 2016 first quarter ended December 31, 2015.

"Our fiscal first quarter performance reflects continued penetration of near-term business verticals beyond textiles, our most mature vertical," stated Dr. James A. Hayward, President and Chief Executive Officer of Applied DNA Sciences. "We are pleased to report revenue growth on a year-over-year basis, which was driven by orders from our Diagnostics and Asset Marking verticals and two government contract awards. As expected, seasonality of the cotton ginning season caused revenue to dip from the fiscal 2015 fourth quarter."

Dr. Hayward continued, "Our DNA-based solutions are applicable to multiple verticals; our momentum was sustained this quarter toward commercial deployment as part of our ongoing strategy to diversify our revenue base as our DNA-based security solutions for supply chains continued to gain traction. The textiles market affords us substantial opportunity and we are expanding our penetration of this market with additional brands and retailers that should translate to greater diversity of textile revenue than we achieved last year."

First Quarter Financial Highlights:

  • Revenues increased 7% for the first quarter of fiscal 2016 to $1.32 million, compared with $1.24 million reported in the first quarter of fiscal 2015, and decreased 67% from the $4.0 million reported in the fourth fiscal quarter ended September 30, 2015.
  • The year-over-year increase in revenue is primarily attributable to DNA manufacturing for the diagnostic market, two ongoing government contracts and an increase in sales for asset and valuables marking. The sequential decrease in revenues resulted primarily from the seasonality of the cotton ginning season to the Company's business.
  • Total operating expenses were $4.2 million, compared with $5.1 million in the prior year's quarter, a decrease of approximately $815 thousand or 16%. The decrease in year-over-year total operating expenses is primarily attributable to a decrease in selling, general and administrative expense partially offset by increases in research and development expense of $194 thousand and depreciation and amortization expenses of $109 thousand. 
  • Net loss for the quarter ended December 31, 2015 was $2.9 million, or $0.13 per share, compared with a net loss of $7.8 million, or $0.51 per share for the quarter ended December 31, 2014 and a net loss of $496 thousand, or $0.02 per share for the quarter ended September 30, 2015.
  • Excluding non-cash expenses, Adjusted EBITDA for the quarter ended December 31, 2015 was negative $2.2 million compared to a negative Adjusted EBITDA of $1.7 million for the same quarter last year and a positive Adjusted EBITDA of $213 thousand in the prior fiscal quarter due mainly to a number of non-recurring expenses of approximately $425,000 incurred during the quarter ended December 31, 2015. See below for information regarding non-GAAP measures.
  • Cash and cash equivalents as of December 31, 2015 totaled $12.4 million as compared to $7.3 million at September 30, 2015. The increase in cash balances is due primarily to the registered direct public offering and concurrent private placement conducted in the quarter that raised gross proceeds of approximately $8.75 million.
  • Net cash used in operating activities in the fiscal first quarter of 2016 was $2.7 million.This compares with $2.4 million the corresponding prior-year period. 

Recent Highlights:

  • The Company was featured in a National Public Radio story, aired yesterday, entitled: "Cotton Sheet Conspiracy Brought Down by DNA Testing". Listen at: http://kvpr.org/post/cotton-sheet-conspiracy-brought-down-dna-testing.
  • The Company announces the formation of a Strategic Advisory Board (SAB) that will provide guidance in specific market verticals. Initially, the SAB will be comprised of two former executives with decades of experience in the pharmaceutical field who will assist the Company in its entry into the pharmaceutical industry, and a globally recognized leader of a major energy utility, who will guide the Company's expansion into the protection of critical infrastructure in power grids and railways.
  • On December 1, the Company announced that it had successfully completed a six-month development project funded by existing defense contracts to incorporate its SigNature® DNA technology into various conductive and non-conductive silicone elastomers. In addition, the project validated the embedding of the Company's SigNature DNA in elastomers for commercial applications, such as those commonly used in the automotive, medical device and toy industries. Subsequent project stages aim for a full commercial launch of select DNA-embedded silicone rubber products.
  • The Company completed DNA marking of plastic master batches used for the generation of fibers in synthetic textiles. Related projects are underway in plastic colorants and molded products.
  • The Company expanded its PartnerProtect™ channel for print media. Completion of multiple pilots forms a cumulative experience that will accelerate delivery to an expanding customer base. Categories include tax stamps for a foreign country, secure labels for United States federal use, inkjet marking and food-grade and pharmaceutical labels.
  • The Company announces the expansion of its fiberTyping® business to a global marketplace. New customers include luxury European men's and women's apparel, top denim lines, outdoor and performance sportswear and apparel brands, and boutique and large retailers of premium pima products. These customers use fiberTyping to diagnose if they have a problem in their supply chain, with the opportunity to solve the problem by using SigNature T® tagging to ensure traceability from point-of-origin to point-of-sale.
  • The Company received Notice of Allowance from the US Patent Office for three additional patents, including an additional patent on the genotyping of mature cotton fibers and textiles.
  • On January 12, 2016, the Company announced that it had signed a Cooperative Research and Development Agreement (CRADA) with the United States Department of Agriculture (USDA). The Agreement is expected to enhance Applied DNA's identification of cotton cultivars including the ability to identify key cultivars for specific cotton growing regions, including those with questionable labor practices.
  • On January 5, 2016, the Company announced a contract with a key distributor in Europe to provide its metal marking product to one of Europe's leading electricity providers. The contract is for a period of two years with an option to extend for a third year and is estimated to be valued at between $130,000 and $260,000 per annum.
  • The Company's Asset Protection Program has advanced westward from its Long Island headquarters to inclusion in four states, more than 250 communities and more than 100 law enforcement agencies. Future sales in this vertical will be supported by its relationship with Security Marketing Resources (SMR) of California.
  • Preparations are near complete to launch the Company's SMR DNA Security Initiative for Asset Protection, with line of sight to 500 US security dealers and their 500,000+ commercial and consumer customers.

Dr. Hayward concluded, "Applied DNA remains well positioned to benefit from the large and growing demand for supply chain security and anti-counterfeiting solutions in fiscal 2016. Our pipeline of pilot projects is expected to continue to deepen the validation of our technology and drive much stronger fundamentals, as evidenced by our success in purifying cotton supply chains. We remain committed to growing the business in a disciplined, structured way that applies our financial resources to maximize returns. As we move to replicate recent successes across verticals with near-term drivers of growth, the growing awareness and interest we are receiving from the marketplace serves to further validate our value proposition and strategy."

Fiscal 2016 First Quarter Conference Call Information

The Company will hold a conference call and webcast to discuss its fiscal 2016 first quarter results on Wednesday, February 10, 2016 at 4:30 PM EST. To participate on the conference call, please follow the instructions below. While every attempt will be made to answer investors' questions on the Q&A portion of the call, due to the large number of expected participants, not all questions may be answered.

To Participate:

Reserve your conference call seat now at: http://dpregister.com/10079875. Conference call dial-in information will be provided upon completion of the registration process.

Live webcast: http://services.choruscall.com/links/apdn160202

Replay (available 1 hour following the conclusion of the live call):

For those investors unable to attend the live call, a copy of the presentation is expected to be posted by end of business on February 10, 2016 and available under the "Investor Information" tab of the company's web site.

Information about Non-GAAP Financial Measures

As used herein, "GAAP" refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company's historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as it allows for greater transparency with respect to key metrics used by management in its financial and operational decision making.

"EBITDA" - is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

"Adjusted EBITDA" - is defined as EBITDA adjusted to exclude (i) change in fair value of warrant liability, (ii) the loss on conversion of promissory notes, (iii) stock-based compensation and (iv) other non-cash expenses.

About Applied DNA Sciences

We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Applied DNA's common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW. 

Forward Looking Statements

The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2015, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Financial Tables Follow

 
 
APPLIED DNA SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
 
    December 31,
2015
    September 30,
2015
 
    (unaudited)        
ASSETS                
Current assets:                
Cash and cash equivalents   $ 12,382,907     $ 7,312,184  
Accounts receivable, net of allowance of $7,140 at December 31, 2015 and September 30, 2015     3,923,997       3,929,517  
Prepaid expenses and other current assets     187,355       293,351  
Total current assets     16,494,259       11,535,052  
Property, plant and equipment, net of accumulated depreciation of $955,765 at December 31, 2015 and $852,867 at September 30, 2015     561,912       572,107  
Other assets:                
Long term accounts receivables     1,500,000       1,500,000  
Deposits     58,488       62,988  
Goodwill     285,386       285,386  
Intangible assets, net of accumulated amortization of $284,816 and $238,368 at December 31, 2015 and September 30, 2015, respectively     1,584,473       1,598,779  
Total Assets   $ 20,484,518     $ 15,554,312  
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current liabilities:                
Accounts payable and accrued liabilities   $ 2,110,995     $ 2,385,006  
Deferred revenue     57,526       282,050  
Total current liabilities     2,168,521       2,667,056  
Long term accounts payable     320,400       320,400  
Total liabilities     2,488,921       2,987,456  
Commitments and contingencies                
Stockholders' Equity                
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2015 and September 30, 2015     -       -  
Series A Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2015 and September 30, 2015     -       -  
Series B Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of December 31, 2015 and September 30, 2015     -       -  
Common stock, par value $0.001 per share; 500,000,000 shares authorized at December 31, 2015 and September 30, 2015; 24,072,092 and 21,504,578 shares issued and outstanding as of December 31, 2015 and September 30, 2015, respectively     24,073       21,505  
Additional paid in capital     232,539,203       224,186,760  
Accumulated deficit     (214,567,679 )     (211,641,409 )
Total stockholders' equity     17,995,597       12,566,856  
Total Liabilities and Stockholders' Equity   $ 20,484,518     $ 15,554,312  
                 
 
APPLIED DNA SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
 
    Three Months Ended December 31,  
    2015     2014  
                 
Revenues   $ 1,324,114     $ 1,241,802  
Operating expenses:                
Selling, general and administrative     3,554,362       4,671,490  
Research and development     471,934       278,288  
Depreciation and amortization     218,346       109,726  
Total operating expenses     4,244,642       5,059,504  
LOSS FROM OPERATIONS     (2,920,528 )     (3,817,702 )
Other income (expense):                
Interest income (expense), net     2,845       (31,875 )
Other (expense) income, net     (8,587 )     (3,685 )
Loss on conversion of promissory notes     -       (980,842 )
Loss on change in fair value of warrant liability     -       (2,994,540 )
Net loss before provision for income taxes     (2,926,270 )     (7,828,644 )
Provision for income taxes     -       -  
NET LOSS   $ (2,926,270 )   $ (7,828,644 )
Net loss per share-basic and diluted   $ (0.13 )   $ (0.51 )
Weighted average shares outstanding-                
  Basic and diluted     22,542,176       15,456,566  
 
 
APPLIED DNA SCIENCES, INC.
CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA
 
(Unaudited)
 
    Three Month Period Ended
    December 31,
    2015     2014     % Variance
                     
Net Loss   $ (2,926,270 )   $ (7,828,644 )    
Interest expense (income), net     (2,845 )     31,875      
Depreciation and amortization     218,346       109,726      
(Gain) loss on change in fair value of warrant liability     -       2,994,540      
Stock based compensation expense     455,110       1,998,524      
Loss on conversion of promissory notes     -       980,842      
Bad debt expense     10,000       2,779      
Total non-cash items     680,611       6,118,286      
Consolidated Adjusted EBITDA (loss)   $ (2,245,659 )   $ (1,710,358 )   31 %
       
       
    Three Month Period Ended  
    September 30,  
    2015  
         
Net Loss   $ (496,034 )
Interest expense (income), net     (3,340 )
Depreciation and amortization     136,496  
(Gain) loss on change in fair value of warrant liability     -  
Stock based compensation expense     562,933  
Loss on conversion of promissory notes     -  
Bad debt expense     13,246  
Total non-cash items     709,335  
Consolidated Adjusted EBITDA (loss)   $ 213,301  

Investor contact:
Debbie Bailey
631-240-8817
debbie.bailey@adnas.com

Sanjay M. Hurry
212-838-3777
LHA
shurry@lhai.com

Media contact:
Susan Forman
Dian Griesel Int'l.
212-825-3210
sforman@dgicomm.com

web: www.adnas.com
twitter: @APDN

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 15

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 94

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 106

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 82

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 77

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 0

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading
Whole-House Remodels Need a Plan Before Any Finishes

Updated Category News Views 98

A remodel gets expensive the minute somebody falls in love with tile before checking what sits behind the wall. Adam Sherman’s central point in the HelloNation article is refreshingly unglamorous: treat the house as one working system before treating it as a collection of rooms crying out for cosmetic rescue. That sounds obvious until you see how often a kitchen...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Unite: Taking Action Against aTyr Pharma's Misconduct

Updated Category News Views 142

Understanding the Case Against aTyr Pharma, Inc. Many investors have faced uncertainty in recent years, particularly in the healthcare sector. aTyr Pharma, Inc. (NASDAQ: ATYR) finds itself at the center of a securities fraud lawsuit, directed by the Schall Law Firm, designed to or encourage investors who may have been adversely impacted by the company's actions to take a...

Continue Reading
BIC Announces Rob Versloot as New CEO for Future Growth

Updated Category News Views 1055

Exciting Leadership Transition at BIC BIC has recently made a significant leadership transition by appointing Rob Versloot as the new Chief Executive Officer. This shift follows an extensive selection process conducted with utmost diligence and care by the Succession Committee under the guidance of Edouard Bich, the Chair of the Board of Directors. Background on Rob...

Continue Reading
Canadian Market Sees Gains as S&P/TSX Composite Hits Records

Updated Category News Views 167

Overview of the Canadian Stock Market Recently, the Canadian stock market has shown significant progress, culminating in a positive trading session that reflected growing investor confidence. The S&P/TSX Composite Index closed the day up by 0.40%, showcasing lively market activity and enthusiasm across various sectors. Sector Performances Fueling Market Gains Key sectors...

Continue Reading
Three Risky Consumer Staples That Might Struggle Soon

Updated Category News Views 153

Overview of Consumer Staples at Risk As recent market analysis highlights, several stocks in the consumer staples sector may be indicating potential challenges that investors should take into account. While consumer staples are generally viewed as safer investments, certain indicators suggest that this perception may not hold for every stock, especially in the current...

Continue Reading
Healthcare IT Outsourcing Market Projected to Reach $122.72 Billion

Updated Category News Views 156

Understanding the Surge in Healthcare IT Outsourcing The Healthcare IT Outsourcing Market signifies a booming ecosystem, anticipated to reach USD 122.72 billion by 2032, with a notable compound annual growth rate (CAGR) of 7.44%. The driving forces behind this remarkable growth are rooted in digital transformation and an increasing demand for operational efficiency....

Continue Reading